Nestle to buy Aimmune Therapeutics for $2.6 billion

Nestle said it was offering $34.50 per share for the remaining 74.4% in peanut allergy treatment maker Aimmune Therapeutics it does not already own, adding a potential blockbuster to its health science portfolio.